Codexis, Inc. (CDXS) Social Stream
Featured Post From StockTwits About CDXS
$CDXS The tone of the conference call was decidedly positive. Their product revenue will be at the high end of guidance and possibly as good as last year, despite a pandemic. Januvia is still the leader in product revenue. Not sure how long before it goes off patent. Starting to see product revenue come in from Tate and Lyle for Tasteva M. Should continue to increase next year. Still anticipating as much as $10 million a year or more from that product alone, but it could take 3 to 5 years to reach that.DJGustave, published November 24, 2020
Lots of information about DNA and RNA polymerase products. Lots of interest from multiple companies. Definitely looking to include this into Covid vaccine production at some point.